Promega SABiosciences Agreement Enables the Most Sensitive Tools for Pathway Analysis
News Aug 18, 2009
Promega and SABiosciences will combine their offerings to provide sensitive tools for interrogating specific cellular pathways via transcription factor reporters.
Under the new agreement Promega recombinant firefly luciferase luc2 gene and a humanized Renilla luciferase (hRluc) gene- the ‘dual luciferases’- will serve as one key reporter system for SABiosciences pathway reporter assays under the Cignal™ moniker.
Cignal transcription reporters from SABiosciences offer the widest selection of pathway activity assays, featuring more than 40 pathway reporters available in both DNA construct and viral particle formats.
“We are pleased to include Promega’s recombinant firefly and humanized Renilla luciferases as reporters in our product lines. They provide the necessary levels of sensitivity for studying the effects of drugs or genetic perturbations on many interesting and biologically relevant cell types.” said Dave Martz, VP of Sales and Marketing at SABiosciences.
The Cignal products with Promega luciferase technology are currently available in tube and plate formats for multiple pathways of biological interest.
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE